A patient's detailed and specific IgE profile can be a very powerful tool to learn more about allergic sensitization and clinical allergies, assessing the risk of severe allergic reactions and a fair indication of how successful you can expect the treatment to be.
Development and progress made in the field of allergy diagnostics have allowed for a new concept, Molecular Allergy, that makes it possible to identify single allergen proteins, i.e. components. The most important clinical utility of this new concept is the ability to reveal whether the sensitization is genuine in nature or if it is due to a cross-reaction to proteins with similar protein structures. With this knowledge you can evaluate the risk of reaction on exposure to different allergen sources.
Diagnosing and determining the severity of allergy
With ImmunoCAP allergens and allergen components, precise, quantitative detection of IgE antibodies is possible that allows the assessment of
- Risk of severe reactions
- Cross-reactivity patterns
- Suitability for specific immunotherapy (SIT).
For some examples of how a risk assessment of food allergies was performed using ImmunoCAP Allergens and Allergen Components, click the call out to the right and read our Case Studies.
For more information, read our folders ImmunoCAP Molecular Allergy (pdf) and Immuno Solid-phase Allergen Chip (ISAC) (pdf).
Phadia Immunology Reference Laboratory (PiRL) Center for Innovation
At PiRL we are committed to providing specialists with the highest quality, most up-to-date laboratory allergy tests available. To visit PiRL please click here or on the link below.
For more detailed information about the concept of Molecular Allergy or information on how or where to order a test, contact your local Phadia representative, click the call-out to the right.
To learn more: